JFS Wealth Advisors’s Harmony Biosciences HRMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$158 Hold
4
– – ﹤0.01% 2118
2026
Q2
$146 Buy
+4
New +$126 ﹤0.01% 2196
2025
Q4
– Sell
-12
Closed -$331 – 1946
2025
Q3
$331 Sell
12
-1
-8% -$34 ﹤0.01% 1805
2025
Q2
$411 Hold
13
– – ﹤0.01% 1730
2025
Q1
$432 Hold
13
– – ﹤0.01% 1786
2024
Q4
$448 Buy
13
+2
+18% +$69 ﹤0.01% 1794
2024
Q3
$440 Hold
11
– – ﹤0.01% 1817
2024
Q2
$332 Buy
11
+7
+175% +$210 ﹤0.01% 1852
2024
Q1
$135 Buy
4
+2
+100% +$64 ﹤0.01% 1926
2023
Q4
$65 Sell
2
-8
-80% -$223 ﹤0.01% 1970
2023
Q3
$328 Sell
10
-1
-9% -$35 ﹤0.01% 1806
2023
Q2
$388 Buy
11
+4
+57% +$138 ﹤0.01% 1794
2023
Q1
$229 Sell
7
-7
-50% -$319 ﹤0.01% 1812
2022
Q4
$771 Buy
14
+5
+56% +$275 ﹤0.01% 1657
2022
Q3
$0 Buy
9
+1
+13% +$49 ﹤0.01% 1813
2022
Q2
$0 Buy
8
+1
+14% +$45 ﹤0.01% 1830
2022
Q1
$0 Buy
7
+6
+600% +$245 ﹤0.01% 1886
2021
Q4
$0 Buy
+1
New +$40 ﹤0.01% 1785

Other funds holding HRMY

JFS Wealth Advisors's HRMY Position: Q3 2026 in Review

JFS Wealth Advisors held its Harmony Biosciences (HRMY) position steady in Q3 2026 at 4 shares worth $158. The position accounts for ﹤0.01% of the portfolio, ranked #2118.

JFS Wealth Advisors first reported a position in HRMY in Q4 2021 and has held it in 18 quarters since. The position peaked at $771 in Q4 2022. 358 funds tracked by Wall St. Rank hold HRMY as of Q3 2026.

  • JFS Wealth Advisors held 4 shares of Harmony Biosciences worth $158 as of Q3 2026.
  • JFS Wealth Advisors left its Harmony Biosciences share count unchanged in Q3 2026.
  • Harmony Biosciences made up ﹤0.01% of JFS Wealth Advisors's portfolio in Q3 2026, its #2118 holding.
  • JFS Wealth Advisors first reported a position in Harmony Biosciences in Q4 2021 and has held it in 18 quarters since.
  • JFS Wealth Advisors's Harmony Biosciences position peaked at $771 in Q4 2022.
  • 358 funds tracked by Wall St. Rank held Harmony Biosciences as of Q3 2026.

Based on JFS Wealth Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.